Diabetes Pro Quarterly - Winter 2021 - 2

Cover Story: Standards of Medical Care in Diabetes-2021 Now Available
continued from previous page

*	Descriptions of barriers to and critical times for
diabetes self-management education and support
(DSMES)
*	Vaccine-specific updates, including those related to
coronavirus disease 2019 (COVID-19)
Other noteworthy updates and additions to the
Standards of Medical Care in Diabetes-2021
include:

Evolving evidence
*	Table 9.1 has been updated and figure 9.1 has
been revised to include dedicated decision
pathways for CKD and HF, with updates to
reflect ADA's Professional Practice Committee's
consensus interpretation of clinical trial data
(Section 9, pages S115-S116).
*	Figure 9.2 has been revised to include assessment
of adequacy of insulin dose and updates regarding
the use of glucagon-like peptide 1 receptor
agonists (Section 9, page S117).
*	Section 10, on cardiovascular disease (CVD)
and risk management, is endorsed for the third
consecutive year by the American College
of Cardiology. Recommendations regarding
treatment in the Cardiovascular Disease
subsection have been revised to include the
evolving evidence from cardiovascular outcomes
trials (Section 10, page S137).

*	Recommendation 11.3 on treatment for CKD
has been divided into three recommendations to
individualize treatment based on renal function
and risk of CVD (Section 11, pages S151-S152).

Using technology in diabetes management
*	The A1C subsection was retitled Glycemic
Assessment, with respective changes to the
recommendations to allow for other glycemic
measures aside from A1C (Section 6, page S73).
*	The Glycemic Goals subsection has also been
revised to include other glycemic measures,
and the recommendation for glycemic
goals for many nonpregnant adults without
significant hypoglycemia has been divided in
two parts to include goals for time in range
(Section 6, page S75).
*	The Continuous Glucose Monitoring Devices
subsection has been revised, and blinded CGM
is now referred to as " professional CGM, " which
refers to clinic-based CGM systems and can
include blinded and real-time devices. Table 7.3
has been updated to reflect this change as well.
(Section 7, pages S87-S90).
*	Recommendations include CGM as useful for
people with diabetes on multiple daily injections
or continuous subcutaneous insulin infusion
and other forms of insulin therapy (with different
levels of evidence) and are not defined by type
of diabetes or age (Section 7, page S87).
*	New recommendations were added on the
use of CGM in youth to the type 1 diabetes in
the Glycemic Control subsection (Section 13,
page S183).

Individualizing patient care
*	Additional information has been included
on SDOH in diabetes to reflect the evidence
presented in " Social Determinants of Health
in Diabetes: A Scientific Review, " published in
November 2020 (doi.org/10.2337/dci20-0053)
(Throughout).
*	The Immunizations subsection has been revised,
and a table was added containing Centers for
Disease Control and Prevention-recommended
vaccinations for people with diabetes (Section 4,
Table 4.5, pages S47-S48).
continued on next page

2

DiabetesPro Quarterly | WINTER 2021
https://care.diabetesjournals.org/content/early/2020/10/31/dci20-0053 https://care.diabetesjournals.org/content/early/2020/10/31/dci20-0053 https://www.doi.org/10.2337/dci20-0053
Diabetes Pro Quarterly - Winter 2021

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Winter 2021
